title: Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients.
abstract: BACKGROUND
  The role of stents, especially of heparin-coated stents for the treatment of stenoses in small coronary arteries, is still unclear. Therefore, we performed this prospective, randomized trial to evaluate the angiographic and clinical outcome after treatment of stenoses in small coronary arteries (2.0 to 2.6 mm) of symptomatic patients.
  
  
  RESULTS
  We randomly assigned 588 patients to angioplasty (n=195), bare stenting (n=196), or heparin-coated stenting (n=197). The primary end point was minimal lumen diameter (MLD) at 6 months. With comparable baseline parameters, the two stent arms showed a larger postinterventional MLD, larger acute gain, and smaller residual percent diameter stenosis, although a residual stenosis of 12+/-16% was achieved in the angioplasty arm, including a 27% crossover rate to stenting. Eighty percent of patients had follow-up angiography, which documented a borderline significantly larger MLD and smaller percent diameter stenosis for the two stent groups (1.34+/-0.48 mm and 42+/-20% after angioplasty, 1.47+/-0.48 mm and 36+/-20% after bare stenting, and 1.45+/-0.54 mm and 38+/-23% after heparin-coated stenting; P=0.049 and P=0.038, respectively), but restenosis rates were not different (32%, 25%, and 30%). Thrombotic events occurred in 1.0% after angioplasty and 0.5% after bare or heparin-coated stenting. Survival without myocardial infarction or target vessel revascularization at 250 days was 84.6% (angioplasty), 88.3% (bare stenting), and 88.3% (heparin-coated stenting; log-rank P=0.39).
  
  
  CONCLUSIONS
  Compared with angioplasty with provisional stenting, bare and heparin-coated stenting confer superior angiographic results and a nonsignificant 24% reduction in clinical events, with no difference between bare and heparin-coated stenting in the treatment of stenoses in small coronary arteries.
authors.affiliation: Cardiology Clinic, University Essen, Essen, Germany. michael.haude@uni-essen.de
authors.forename: Michael
authors.initials: M
authors.lastname: Haude
authors.forename: Thomas F M
authors.initials: TF
authors.lastname: Konorza
authors.forename: Uldis
authors.initials: U
authors.lastname: Kalnins
authors.forename: Andrejs
authors.initials: A
authors.lastname: Erglis
authors.forename: Kari
authors.initials: K
authors.lastname: Saunamäki
authors.forename: Helmut D
authors.initials: HD
authors.lastname: Glogar
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
authors.forename: Robert
authors.initials: R
authors.lastname: Gil
authors.forename: Antonio
authors.initials: A
authors.lastname: Serra
authors.forename: Hans G
authors.initials: HG
authors.lastname: Richardt
authors.forename: Peter
authors.initials: P
authors.lastname: Sick
authors.forename: Raimund
authors.initials: R
authors.lastname: Erbel
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D003331:Coronary Vessels / Q000033:anatomy & histology / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin